Recombinant Human Interleukin-36 beta, 157a.a.

Synonyms FIL1 eta, IL-1 eta, IL-1F8, IL-1H2

Accession Q9NZH7-2

GeneID 27177

Source Escherichia coli.

Molecular Weight Approximately 17.7kDa, a single non-glycosylated polypeptide chain containing 157 amino acids.

Quantity 2µg/10µg/1mg

AA Sequence MNPQREAAPK SYAIRDSRQM VWVLSGNSLI AAPLSRSIKP VTLHLIACRD TEFSDKEKGN MVYLGIKGKD LCLFCAEIQG KPTLQLKEKN IMDLYVEKKA QKPFLFFHNK EGSTSVFQSV SYPGWFIATS TTSGQPIFLT KERGITNNTN FYLDSVE

Purity > 97 % by SDS-PAGE and HPLC analyses.

Biological Activity Fully biologically active when compared to standard. The specific activity is determined by its binding ability in a functional ELISA. Immobilized rHuIL-36β at 1 µg/mL can bind recombinant human IL-1 Rrp2 Fc Chimera with a range of 0.15-5 µg/mL.

Physical Appearance Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.

Endotoxin Less than 1 EU/μg of rHuIL-36β, 157a.a. as determined by LAL method.

Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.

- 1 month, 2 to 8 °C under sterile conditions after reconstitution.

- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Usage This material is offered by Shanghai PrimeGene Bio-Tech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.

SDS-PAGE

Reference 1. Nicklin MJ, Barton JL, Nguyen M, et al. 2002. Genomics. 79:718-25.

2. Dinarello C, Arend W, Sims J, et al. 2010. Nat Immunol. 11:973.

3. Magne D, Palmer G, Barton JL, et al. 2006. Arthritis Res Ther. 8:R80.

4. van Asseldonk EJ, Stienstra R, Koenen TB, et al. 2010. Obesity (Silver Spring). 18:2234-6.

5. Johnston A, Xing X, Guzman AM, et al. 2011. J Immunol. 186:2613-22.

Background Interleukin-36 (IL-36) is a pro-inflammatory cytokine which plays an important role in the pathophysiology of several diseases. IL-36α, IL-36β, and IL-36γ (formerly IL-1F6, IL-1F8, and IL-1F9) are IL-1 family members that signal through the IL-1 receptor family members IL-1Rrp2 (IL-1RL2) and IL-1RAcP. IL-36 beta is reported to be expressed at higher levels in psoriatic plaques than in symptomless psoriatic skin or healthy control skin. Furthermore, it can stimulate production of interleukin-6 and interleukin-8 in synovial fibroblasts, articular chondrocytes and mature adipocytes. Two alternatively spliced transcript variants encode distinct (164 or 157 residues) protein isoforms that differ in their C-terminal 70 amino acid residues have been reported and IL-36β isoform 2 is synthesized as a 157 a.a. protein. Specifically, human IL-36β shares low sequence identity with IL-1β, IL-36RA, IL-36α and IL-36γ.